SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/240441"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/240441" > Treatment of stage ...

  • Tandstad, T.St. Olav’s University Hospital,St Olavs University Hospital, Norway (författare)

Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)

  • Artikel/kapitelEngelska2016

Förlag, utgivningsår, omfång ...

  • Elsevier BV,2016

Nummerbeteckningar

  • LIBRIS-ID:oai:gup.ub.gu.se/240441
  • https://gup.ub.gu.se/publication/240441URI
  • https://doi.org/10.1093/annonc/mdw164DOI
  • https://lup.lub.lu.se/record/3e3d6197-3796-4f8a-8790-eb4fe9ad479cURI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-130658URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:133952737URI

Kompletterande språkuppgifter

  • Språk:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies|Research Committee at St Olavs Hospital, Trondheim; Swedish Cancer Society; Swedish Association of Local Authorities and Regions; Norwegian Regional Health Authorities; Norwegian Urological Cancer Group
  • A total of 1118 patients with clinical stage I seminoma one course of adjuvant carboplatin or managed by surveillance were included. Stromal invasion of rete testis and tumor size > 4 cm are confirmed as risk factors predicting relapse. Relapse rates following one course of adjuvant carboplatin is high and there is need to explore more effective adjuvant treatment options in patients with seminoma.The purpose of the protocol was to reduce the treatment burden in clinical stage I (CSI) seminoma by offering risk-adapted treatment. The protocol aimed to prospectively validate the proposed risk factors for relapse, stromal invasion of the rete testis and tumor diameter > 4 cm, and to evaluate the efficacy of one course of adjuvant carboplatin. From 2007 to 2010, 897 patients were included in a prospective, population-based, risk-adapted treatment protocol implementing one course of adjuvant carboplatin AUC7 (>n = 469) or surveillance (>n = 422). In addition, results from 221 patients receiving carboplatin between 2004 and 2007 are reported. At a median follow-up of 5.6 years, 69 relapses have occurred. Stromal invasion of the rete testis [hazard ratio (HR) 1.9, >P = 0.011] and tumor diameter > 4 cm (HR 2.7, >P < 0.001) were identified as risk factors predicting relapse. In patients without risk factors, the relapse rate (RR) was 4.0% for patients managed by surveillance and 2.2% in patients receiving adjuvant carboplatin. In patients with one or two risk factors, the RR was 15.5% in patients managed by surveillance and 9.3% in patients receiving adjuvant carboplatin. We found no increased RR in patients receiving carboplatin < 7 x AUC compared with that in patients receiving a parts per thousand yen7 x AUC. Stromal invasion in the rete testis and tumor diameter > 4 cm are risk factors for relapse in CSI seminoma. Patients without risk factors have a low RR and adjuvant therapy is not justified in these patients. The efficacy of adjuvant carboplatin is relatively low and there is need to explore more effective adjuvant treatment options in patients with high-risk seminoma. The data do not support the concept of a steep dose response for adjuvant carboplatin.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Ståhl, OlofLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital, Sweden(Swepub:lu)kir-ost (författare)
  • Dahl, O.University of Bergen, Norway; Haukeland Hospital, Norway (författare)
  • Haugnes, H. S.University of Tromso, Norway; University Hospital North Norway, Norway (författare)
  • Håkansson, U.Lund University,Lunds universitet,Urologi,Forskargrupper vid Lunds universitet,Urology,Lund University Research Groups,Skåne University Hospital, Sweden(Swepub:lu)kir-uha (författare)
  • Karlsdottir, A.Haukeland University Hospital,Haukeland Hospital, Norway (författare)
  • Kjellman, A.Karolinska Institutet (författare)
  • Langberg, C. W.Oslo University Hospital, Norway (författare)
  • Laurell, A.University of Uppsala Hospital, Sweden(Swepub:lu)med-al21 (författare)
  • Oldenburg, J.Akershus University Hospital, Norway; University of Oslo, Norway (författare)
  • Solberg, A.St. Olav’s University Hospital,St Olavs University Hospital, Norway (författare)
  • Söderström, K.Norrland University Hospital, Sweden(Swepub:lu)kosu-kso (författare)
  • Stierner, Ulrika,1952University of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology,Sahlgrens University Hospital, Sweden; University of Gothenburg, Sweden(Swepub:gu)xstiul (författare)
  • Cavallin-Ståhl, E.Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital, Sweden(Swepub:lu)onk-ecs (författare)
  • Wahlqvist, R.Oslo University Hospital, Norway (författare)
  • Wall, NajmeLinköpings universitet,Avdelningen för kliniska vetenskaper,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US(Swepub:liu)najwa86 (författare)
  • Cohn-Cedermark, G.Karolinska Institutet,Karolinska Institute,Karolinska Institute, Sweden; Karolinska University Hospital, Sweden (författare)
  • St. Olav’s University HospitalSt Olavs University Hospital, Norway (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Annals of Oncology: Elsevier BV27:7, s. 1299-13040923-75341569-8041

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy